4D Molecular Therapeutics (FDMT) Change in Acquisitions & Divestments (2021 - 2026)

4D Molecular Therapeutics (FDMT) has reported Change in Acquisitions & Divestments for 6 consecutive years, with $102.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 38.56% year-over-year to $102.4 million; the TTM figure through Mar 2026 stood at $286.1 million (down 10.83% YoY), while the FY2025 annual figure was $350.4 million, up 107.33% from the prior year.
• Change in Acquisitions & Divestments advanced to $102.4 million in Q1 2026 per FDMT's latest filing, from $49.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $205.3 million in Q3 2022 and bottomed at -$135.2 million in Q4 2022.
• Historically, Change in Acquisitions & Divestments has averaged $55.5 million across 5 years, with a median of $55.5 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments sank 2803.88% — and 2025, when it surged 1027.88%.
• 4D Molecular Therapeutics' Change in Acquisitions & Divestments stood at -$135.2 million in 2022, then jumped by 121.09% to $28.5 million in 2023, then surged by 130.72% to $65.8 million in 2024, then dropped by 25.24% to $49.2 million in 2025, then soared by 108.19% to $102.4 million in 2026.
• Business Quant data shows FDMT's Change in Acquisitions & Divestments at $102.4 million in Q1 2026, $49.2 million in Q4 2025, and $32.9 million in Q3 2025.